Explore how AI-driven multiomics is reshaping drug discovery and personalized medicine development through innovative data ...
Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an ...
AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci (ABSI), a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a ...
InSilico Medicine Cayman TopCo ( ($HK:3696) ) has issued an announcement. InSilico Medicine has entered into a multi-year research and development ...
(Reuters) -Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near ...
Insilico Medicine announced the milestone in its collaboration with Hisun Pharmaceutical Co., Ltd. (“Hisun” 600267.SH). Leveraging its proprietary Pharma.AI platform, Insilico successfully nominated ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
RAMAT GAN, Israel, Oct. 23, 2025 /PRNewswire/ -- Protai, www.protai.bio, a structural proteomics and AI-driven biotech, announced its participation in four major scientific conferences this October, ...
The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback